dbPTM

IPO5_HUMAN - PTM Information in dbPTM

Basic Information of Protein

Overview of Protein Modification Sites with Functional and Structural Information
UniProt ID	IPO5_HUMAN
UniProt AC	O00410
Protein Name	Importin-5
Gene Name	IPO5
Organism	Homo sapiens (Human).
Sequence Length	1097
Subcellular Localization	Cytoplasm. Nucleus. Nucleus, nucleolus. Nucleus nuclear rim. Found particularly in the nuclear rim and nucleolus.
Protein Description	Functions in nuclear protein import as nuclear transport receptor. Serves as receptor for nuclear localization signals (NLS) in cargo substrates. Is thought to mediate docking of the importin/substrate complex to the nuclear pore complex (NPC) through binding to nucleoporin and the complex is subsequently translocated through the pore by an energy requiring, Ran-dependent mechanism. At the nucleoplasmic side of the NPC, Ran binds to the importin, the importin/substrate complex dissociates and importin is re-exported from the nucleus to the cytoplasm where GTP hydrolysis releases Ran. The directionality of nuclear import is thought to be conferred by an asymmetric distribution of the GTP- and GDP-bound forms of Ran between the cytoplasm and nucleus (By similarity). Mediates the nuclear import of ribosomal proteins RPL23A, RPS7 and RPL5. Binds to a beta-like import receptor binding (BIB) domain of RPL23A. In vitro, mediates nuclear import of H2A, H2B, H3 and H4 histones. Binds to CPEB3 and mediates its nuclear import following neuronal stimulation (By similarity). In case of HIV-1 infection, binds and mediates the nuclear import of HIV-1 Rev..
Protein Sequence	MAAAAAEQQQFYLLLGNLLSPDNVVRKQAEETYENIPGQSKITFLLQAIRNTTAAEEARQMAAVLLRRLLSSAFDEVYPALPSDVQTAIKSELLMIIQMETQSSMRKKVCDIAAELARNLIDEDGNNQWPEGLKFLFDSVSSQNVGLREAALHIFWNFPGIFGNQQQHYLDVIKRMLVQCMQDQEHPSIRTLSARATAAFILANEHNVALFKHFADLLPGFLQAVNDSCYQNDDSVLKSLVEIADTVPKYLRPHLEATLQLSLKLCGDTSLNNMQRQLALEVIVTLSETAAAMLRKHTNIVAQTIPQMLAMMVDLEEDEDWANADELEDDDFDSNAVAGESALDRMACGLGGKLVLPMIKEHIMQMLQNPDWKYRHAGLMALSAIGEGCHQQMEGILNEIVNFVLLFLQDPHPRVRYAACNAVGQMATDFAPGFQKKFHEKVIAALLQTMEDQGNQRVQAHAAAALINFTEDCPKSLLIPYLDNLVKHLHSIMVLKLQELIQKGTKLVLEQVVTSIASVADTAEEKFVPYYDLFMPSLKHIVENAVQKELRLLRGKTIECISLIGLAVGKEKFMQDASDVMQLLLKTQTDFNDMEDDDPQISYMISAWARMCKILGKEFQQYLPVVMGPLMKTASIKPEVALLDTQDMENMSDDDGWEFVNLGDQQSFGIKTAGLEEKSTACQMLVCYAKELKEGFVEYTEQVVKLMVPLLKFYFHDGVRVAAAESMPLLLECARVRGPEYLTQMWHFMCDALIKAIGTEPDSDVLSEIMHSFAKCIEVMGDGCLNNEHFEELGGILKAKLEEHFKNQELRQVKRQDEDYDEQVEESLQDEDDNDVYILTKVSDILHSIFSSYKEKVLPWFEQLLPLIVNLICPHRPWPDRQWGLCIFDDVIEHCSPASFKYAEYFLRPMLQYVCDNSPEVRQAAAYGLGVMAQYGGDNYRPFCTEALPLLVRVIQSADSKTKENVNATENCISAVGKIMKFKPDCVNVEEVLPHWLSWLPLHEDKEEAVQTFNYLCDLIESNHPIVLGPNNTNLPKIFSIIAEGEMHEAIKHEDPCAKRLANVVRQVQTSGGLWTECIAQLSPEQQAAIQELLNSA

Experimental Post-Translational Modification Sites

* ASA = Accessible Surface Area

Locations	Modification	Substrate Peptides & Secondary Structure	ASA (%)	Reference
2	Acetylation	------MAAAAAEQQ ------CCHHHHHHH	19.67	19413330
20	Phosphorylation	LLLGNLLSPDNVVRK HHHHHCCCCCHHHHH	33.11	20068231
27	Ubiquitination	SPDNVVRKQAEETYE CCCHHHHHHHHHHHH	42.10	-
32	Phosphorylation	VRKQAEETYENIPGQ HHHHHHHHHHCCCCH	27.86	28152594
33	Phosphorylation	RKQAEETYENIPGQS HHHHHHHHHCCCCHH	15.40	28152594
38	Phosphorylation	ETYENIPGQSKITFL HHHHCCCCHHHHHHH	40.37	20068231
40	Phosphorylation	YENIPGQSKITFLLQ HHCCCCHHHHHHHHH	31.75	28152594
41	Ubiquitination	ENIPGQSKITFLLQA HCCCCHHHHHHHHHH	37.57	-
45	Ubiquitination	GQSKITFLLQAIRNT CHHHHHHHHHHHHCC	2.31	-
45 (in isoform 3)	Ubiquitination	-	2.31	-
47 (in isoform 2)	Ubiquitination	-	36.57	-
48 (in isoform 2)	Ubiquitination	-	11.59	-
51	Phosphorylation	FLLQAIRNTTAAEEA HHHHHHHCCCHHHHH	35.35	-
51 (in isoform 3)	Phosphorylation	-	35.35	27642862
61	Sulfoxidation	AAEEARQMAAVLLRR HHHHHHHHHHHHHHH	1.84	28183972
71	Phosphorylation	VLLRRLLSSAFDEVY HHHHHHHHHHHHHHH	24.98	18452278
72	Phosphorylation	LLRRLLSSAFDEVYP HHHHHHHHHHHHHHC	32.69	-
74 (in isoform 2)	Ubiquitination	-	9.94	-
78	Phosphorylation	SSAFDEVYPALPSDV HHHHHHHHCCCCHHH	4.83	-
83	Phosphorylation	EVYPALPSDVQTAIK HHHCCCCHHHHHHHH	51.79	18452278
89	Phosphorylation	PSDVQTAIKSELLMI CHHHHHHHHHHHHHH	5.99	18452278
95	Sulfoxidation	AIKSELLMIIQMETQ HHHHHHHHHHHHHCC	3.87	28465586
96	Phosphorylation	IKSELLMIIQMETQS HHHHHHHHHHHHCCH	1.67	-
99	Sulfoxidation	ELLMIIQMETQSSMR HHHHHHHHHCCHHHH	4.19	28465586
101	Phosphorylation	LMIIQMETQSSMRKK HHHHHHHCCHHHHHH	28.54	18452278
108	Ubiquitination	TQSSMRKKVCDIAAE CCHHHHHHHHHHHHH	37.42	-
110	Glutathionylation	SSMRKKVCDIAAELA HHHHHHHHHHHHHHH	4.26	22555962
125 (in isoform 3)	Ubiquitination	-	32.70	-
126	Ubiquitination	NLIDEDGNNQWPEGL HHCCCCCCCCCCCHH	50.25	-
126 (in isoform 3)	Ubiquitination	-	50.25	-
139	Phosphorylation	GLKFLFDSVSSQNVG HHHHHHHHHCCCCCC	19.30	21406692
141	Phosphorylation	KFLFDSVSSQNVGLR HHHHHHHCCCCCCHH	30.11	21406692
142	Phosphorylation	FLFDSVSSQNVGLRE HHHHHHCCCCCCHHH	24.50	21406692
188	Phosphorylation	MQDQEHPSIRTLSAR HCCCCCCCHHHHHHH	26.98	24719451
238	Ubiquitination	QNDDSVLKSLVEIAD CCCHHHHHHHHHHHH	39.32	-
239	Phosphorylation	NDDSVLKSLVEIADT CCHHHHHHHHHHHHH	33.22	23911959
256	Ubiquitination	KYLRPHLEATLQLSL HHHHHHHHHHHHHHH	36.25	-
257	Phosphorylation	YLRPHLEATLQLSLK HHHHHHHHHHHHHHH	21.70	-
258	Phosphorylation	LRPHLEATLQLSLKL HHHHHHHHHHHHHHH	12.98	20068231
274	Sulfoxidation	GDTSLNNMQRQLALE CCCCCHHHHHHHHHH	3.19	21406390
304	Phosphorylation	HTNIVAQTIPQMLAM HHHHHHHHHHHHHHH	25.53	17192257
322	Phosphorylation	LEEDEDWANADELED CCCCCCCCCCHHCCC	17.41	18691976
371	Ubiquitination	MQMLQNPDWKYRHAG HHHHHCCCHHHHHHH	63.15	-
371 (in isoform 3)	Ubiquitination	-	63.15	-
420	Glutathionylation	PRVRYAACNAVGQMA HHHHHHHHHHHHHHH	2.27	22555962
436	Acetylation	DFAPGFQKKFHEKVI CCCCCHHHHHHHHHH	55.96	23749302
436	Ubiquitination	DFAPGFQKKFHEKVI CCCCCHHHHHHHHHH	55.96	22053931
450	Sulfoxidation	IAALLQTMEDQGNQR HHHHHHHHHHHCCHH	3.26	28183972
454	Acetylation	LQTMEDQGNQRVQAH HHHHHHHCCHHHHHH	44.55	-
455 (in isoform 3)	Ubiquitination	-	22.35	-
473	Glutathionylation	LINFTEDCPKSLLIP HHHCCCCCCHHHHHH	3.58	22555962
476	Phosphorylation	FTEDCPKSLLIPYLD CCCCCCHHHHHHHHH	17.35	27499020
488 (in isoform 2)	Ubiquitination	-	22.69	21890473
491	Phosphorylation	NLVKHLHSIMVLKLQ HHHHHHHHHHHHHHH	20.81	21060948
494	Phosphorylation	KHLHSIMVLKLQELI HHHHHHHHHHHHHHH	3.98	-
494 (in isoform 3)	Phosphorylation	-	3.98	27251275
505	Phosphorylation	QELIQKGTKLVLEQV HHHHHHCCHHHHHHH	28.39	22210691
509	Phosphorylation	QKGTKLVLEQVVTSI HHCCHHHHHHHHHHH	5.73	-
514	Phosphorylation	LVLEQVVTSIASVAD HHHHHHHHHHHHHHH	18.63	30622161
515	Phosphorylation	VLEQVVTSIASVADT HHHHHHHHHHHHHHH	12.44	30622161
518	Phosphorylation	QVVTSIASVADTAEE HHHHHHHHHHHHHHH	19.03	22210691
521	Ubiquitination	TSIASVADTAEEKFV HHHHHHHHHHHHHCC	44.27	-
521 (in isoform 3)	Ubiquitination	-	44.27	-
522	Phosphorylation	SIASVADTAEEKFVP HHHHHHHHHHHHCCC	26.65	22210691
530	Phosphorylation	AEEKFVPYYDLFMPS HHHHCCCHHHHHHHH	12.33	-
548	Acetylation	IVENAVQKELRLLRG HHHHHHHHHHHHHCC	52.71	26051181
548	Phosphorylation	IVENAVQKELRLLRG HHHHHHHHHHHHHCC	52.71	-
548	Ubiquitination	IVENAVQKELRLLRG HHHHHHHHHHHHHCC	52.71	2189047
548 (in isoform 1)	Ubiquitination	-	52.71	21890473
549 (in isoform 3)	Phosphorylation	-	23.25	27642862
556	Ubiquitination	ELRLLRGKTIECISL HHHHHCCCCHHHHHH	39.64	-
557	Phosphorylation	LRLLRGKTIECISLI HHHHCCCCHHHHHHH	25.49	20068231
560	Glutathionylation	LRGKTIECISLIGLA HCCCCHHHHHHHHHH	1.95	22555962
560	S-palmitoylation	LRGKTIECISLIGLA HCCCCHHHHHHHHHH	1.95	29575903
562	Phosphorylation	GKTIECISLIGLAVG CCCHHHHHHHHHHHC	26.12	20068231
566	Ubiquitination	ECISLIGLAVGKEKF HHHHHHHHHHCHHHH	2.50	-
566 (in isoform 3)	Ubiquitination	-	2.50	21890473
574	Sulfoxidation	AVGKEKFMQDASDVM HHCHHHHCCCHHHHH	5.37	21406390
574	Ubiquitination	AVGKEKFMQDASDVM HHCHHHHCCCHHHHH	5.37	-
574 (in isoform 3)	Ubiquitination	-	5.37	-
578	Phosphorylation	EKFMQDASDVMQLLL HHHCCCHHHHHHHHH	38.74	20068231
611 (in isoform 2)	Ubiquitination	-	1.79	-
613	Acetylation	SAWARMCKILGKEFQ HHHHHHHHHHCHHHH	31.46	25953088
613	Malonylation	SAWARMCKILGKEFQ HHHHHHHHHHCHHHH	31.46	26320211
617	Ubiquitination	RMCKILGKEFQQYLP HHHHHHCHHHHHHHH	52.49	-
627	Sulfoxidation	QQYLPVVMGPLMKTA HHHHHHHHCCHHCCC	4.69	28465586
630 (in isoform 2)	Ubiquitination	-	4.56	21890473
631	Sulfoxidation	PVVMGPLMKTASIKP HHHHCCHHCCCCCCC	4.00	28465586
631	Ubiquitination	PVVMGPLMKTASIKP HHHHCCHHCCCCCCC	4.00	-
631 (in isoform 3)	Ubiquitination	-	4.00	-
633	Phosphorylation	VMGPLMKTASIKPEV HHCCHHCCCCCCCCE	16.21	18669648
635	Phosphorylation	GPLMKTASIKPEVAL CCHHCCCCCCCCEEE	36.05	28464451
640 (in isoform 3)	Phosphorylation	-	6.53	27642862
645	Phosphorylation	PEVALLDTQDMENMS CCEEEECCCCCCCCC	26.83	28464451
651	Phosphorylation	DTQDMENMSDDDGWE CCCCCCCCCCCCCCE	2.71	18669648
652	Phosphorylation	TQDMENMSDDDGWEF CCCCCCCCCCCCCEE	49.85	25159151
663	Phosphorylation	GWEFVNLGDQQSFGI CCEEEECCCHHCCCC	26.02	-
667	Phosphorylation	VNLGDQQSFGIKTAG EECCCHHCCCCCCCC	21.58	28176443
670	Phosphorylation	GDQQSFGIKTAGLEE CCHHCCCCCCCCCCC	3.18	18452278
670 (in isoform 3)	Phosphorylation	-	3.18	27251275
671	Ubiquitination	DQQSFGIKTAGLEEK CHHCCCCCCCCCCCC	32.47	-
678	Ubiquitination	KTAGLEEKSTACQML CCCCCCCCCHHHHHH	43.67	-
680	Phosphorylation	AGLEEKSTACQMLVC CCCCCCCHHHHHHHH	42.39	21712546
687	Glutathionylation	TACQMLVCYAKELKE HHHHHHHHHHHHHHC	2.11	22555962
689	Ubiquitination	CQMLVCYAKELKEGF HHHHHHHHHHHHCCH	8.17	-
690	Acetylation	QMLVCYAKELKEGFV HHHHHHHHHHHCCHH	36.78	26051181
690	Ubiquitination	QMLVCYAKELKEGFV HHHHHHHHHHHCCHH	36.78	-
690 (in isoform 1)	Ubiquitination	-	36.78	21890473
693	Acetylation	VCYAKELKEGFVEYT HHHHHHHHCCHHHHH	57.81	26051181
693	Ubiquitination	VCYAKELKEGFVEYT HHHHHHHHCCHHHHH	57.81	-
696	Ubiquitination	AKELKEGFVEYTEQV HHHHHCCHHHHHHHH	3.86	-
696 (in isoform 3)	Ubiquitination	-	3.86	-
698	Phosphorylation	ELKEGFVEYTEQVVK HHHCCHHHHHHHHHH	44.47	-
699	Phosphorylation	LKEGFVEYTEQVVKL HHCCHHHHHHHHHHH	15.41	-
700	Phosphorylation	KEGFVEYTEQVVKLM HCCHHHHHHHHHHHH	13.36	-
708	Ubiquitination	EQVVKLMVPLLKFYF HHHHHHHHHHHHHHC	4.35	-
708 (in isoform 3)	Ubiquitination	-	4.35	21890473
711	Ubiquitination	VKLMVPLLKFYFHDG HHHHHHHHHHHCCCC	2.70	-
711 (in isoform 3)	Ubiquitination	-	2.70	-
717	Phosphorylation	LLKFYFHDGVRVAAA HHHHHCCCCCCHHHH	47.59	-
718	Phosphorylation	LKFYFHDGVRVAAAE HHHHCCCCCCHHHHH	10.68	-
727	Sulfoxidation	RVAAAESMPLLLECA CHHHHHHHHHHHHHH	1.72	21406390
730	Ubiquitination	AAESMPLLLECARVR HHHHHHHHHHHHHHH	2.89	-
733	Glutathionylation	SMPLLLECARVRGPE HHHHHHHHHHHHCHH	2.71	22555962
767	Phosphorylation	EPDSDVLSEIMHSFA CCCHHHHHHHHHHHH	25.56	28348404
793	Ubiquitination	NNEHFEELGGILKAK CCHHHHHHHHHHHHH	6.32	-
800	Ubiquitination	LGGILKAKLEEHFKN HHHHHHHHHHHHHCC	55.64	-
806	Acetylation	AKLEEHFKNQELRQV HHHHHHHCCHHHHHH	60.68	25953088
811	Methylation	HFKNQELRQVKRQDE HHCCHHHHHHHHCCC	38.19	-
818	Ubiquitination	RQVKRQDEDYDEQVE HHHHHCCCCHHHHHH	50.56	-
818 (in isoform 3)	Ubiquitination	-	50.56	-
820	Phosphorylation	VKRQDEDYDEQVEES HHHCCCCHHHHHHHH	21.23	23403867
824	Ubiquitination	DEDYDEQVEESLQDE CCCHHHHHHHHHCCC	9.19	-
824 (in isoform 3)	Ubiquitination	-	9.19	-
827	Phosphorylation	YDEQVEESLQDEDDN HHHHHHHHHCCCCCC	20.16	25159151
829	Methylation	EQVEESLQDEDDNDV HHHHHHHCCCCCCCE	62.42	-
837	Phosphorylation	DEDDNDVYILTKVSD CCCCCCEEEEEHHHH	7.96	23663014
838 (in isoform 3)	Phosphorylation	-	3.85	27642862
840	Phosphorylation	DNDVYILTKVSDILH CCCEEEEEHHHHHHH	21.60	29691806
843	Phosphorylation	VYILTKVSDILHSIF EEEEEHHHHHHHHHH	22.08	29396449
845	Phosphorylation	ILTKVSDILHSIFSS EEEHHHHHHHHHHHH	2.65	17081983
845 (in isoform 3)	Phosphorylation	-	2.65	24719451
848	Phosphorylation	KVSDILHSIFSSYKE HHHHHHHHHHHHHHH	23.14	29396449
851	Phosphorylation	DILHSIFSSYKEKVL HHHHHHHHHHHHHHH	30.96	29396449
852	Phosphorylation	ILHSIFSSYKEKVLP HHHHHHHHHHHHHHH	29.49	29396449
853	Phosphorylation	LHSIFSSYKEKVLPW HHHHHHHHHHHHHHH	23.20	29396449
854	Succinylation	HSIFSSYKEKVLPWF HHHHHHHHHHHHHHH	53.67	23954790
855 (in isoform 3)	Phosphorylation	-	39.92	27642862
899	Phosphorylation	IEHCSPASFKYAEYF HHHCCHHHHHHHHHH	26.17	24719451
961	Acetylation	VIQSADSKTKENVNA HHHCCCCCCCCCCCC	65.25	25953088
963	Ubiquitination	QSADSKTKENVNATE HCCCCCCCCCCCCCH	51.53	-
972	Glutathionylation	NVNATENCISAVGKI CCCCCHHHHHHHHHH	1.80	22555962
972	S-nitrosylation	NVNATENCISAVGKI CCCCCHHHHHHHHHH	1.80	2212679
978	Acetylation	NCISAVGKIMKFKPD HHHHHHHHHHCCCCC	32.78	25953088
981	Ubiquitination	SAVGKIMKFKPDCVN HHHHHHHCCCCCCCC	54.42	-
981 (in isoform 3)	Ubiquitination	-	54.42	-
996	Ubiquitination	VEEVLPHWLSWLPLH HHHHHHHHHHCCCCC	7.08	-
1040	Phosphorylation	TNLPKIFSIIAEGEM CCCCHHHHHHHCCHH	19.29	-
1052	Acetylation	GEMHEAIKHEDPCAK CHHHHHHHCCCHHHH	48.25	25953088

Upstream regulatory proteins (kinases for phosphorylation sites, E3 ubiquitin ligases of ubiquitination sites, ...)

Modified Location	Modified Residue	Modification	Type of Upstream Proteins	Gene Name of Upstream Proteins	UniProt AC of Upstream Proteins	Sources
Oops, there are no upstream regulatory protein records of IPO5_HUMAN !!

Functions of PTM Sites

Modified Location	Modified Residue	Modification	Function	Reference
Oops, there are no descriptions of PTM sites of IPO5_HUMAN !!

Disease-associated PTM Sites based on SAP

* Distance = the distance between SAP position and PTM sites.

Modified Location	Modification	Variant Position (Distance <= 10)	Residue Change	SAP	Related Disease	Reference
Oops, there are no SNP-PTM records of IPO5_HUMAN !!

Protein-Protein Interaction

Interacting Protein	Gene Name	Interaction Type	PPI Reference
NU214_HUMAN	NUP214	physical	9114010
NU153_HUMAN	NUP153	physical	9114010
RAN_HUMAN	RAN	physical	9114010
TNPO1_HUMAN	TNPO1	physical	22939629
RL7_HUMAN	RPL7	physical	20828572
MUC1_HUMAN	MUC1	physical	17500061
WASL_HUMAN	WASL	physical	21988832
HXK2_HUMAN	HK2	physical	22863883
CAND1_HUMAN	CAND1	physical	26344197
CLH1_HUMAN	CLTC	physical	26344197
XPO2_HUMAN	CSE1L	physical	26344197
DCA13_HUMAN	DCAF13	physical	26344197
DDX56_HUMAN	DDX56	physical	26344197
FBRL_HUMAN	FBL	physical	26344197
DHB12_HUMAN	HSD17B12	physical	26344197
IPO7_HUMAN	IPO7	physical	26344197
IPO9_HUMAN	IPO9	physical	26344197
IMA5_HUMAN	KPNA1	physical	26344197
IMA6_HUMAN	KPNA5	physical	26344197
IMB1_HUMAN	KPNB1	physical	26344197
MCM7_HUMAN	MCM7	physical	26344197
RAN_HUMAN	RAN	physical	26344197
RPN1_HUMAN	RPN1	physical	26344197
RPN2_HUMAN	RPN2	physical	26344197
SCAM3_HUMAN	SCAMP3	physical	26344197
S61A1_HUMAN	SEC61A1	physical	26344197
1433S_HUMAN	SFN	physical	26344197
TNPO1_HUMAN	TNPO1	physical	26344197
QCR2_HUMAN	UQCRC2	physical	26344197
XPO1_HUMAN	XPO1	physical	26344197
IMA5_HUMAN	KPNA1	physical	12861017

Drug and Disease Associations

Kegg Disease
There are no disease associations of PTM sites.
OMIM Disease
There are no disease associations of PTM sites.
Kegg Drug
There are no disease associations of PTM sites.
DrugBank
There are no disease associations of PTM sites.

Regulatory Network of IPO5_HUMAN

Related Literatures of Post-Translational Modification

Acetylation
Reference	PubMed
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND MASS SPECTROMETRY.	19413330 [Abstract]
Phosphorylation
Reference	PubMed
"Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-827, AND MASSSPECTROMETRY.	19690332 [Abstract]
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-827, AND MASSSPECTROMETRY.	18669648 [Abstract]
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-304; SER-652 ANDSER-827, AND MASS SPECTROMETRY.	18691976 [Abstract]
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-827, AND MASSSPECTROMETRY.	17081983 [Abstract]